Martin Fromm - Biography#

Martin Fromm studied medicine at the Friedrich-Alexander-University Erlangen-Nuremberg (FAU, Erlangen, Germany). From 1992 to 1996 he worked as a post doctoral fellow at the Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology (Stuttgart, IKP, Germany). Thereafter, he joined funded by the German Research Council (DFG) the Division of Clinical Pharmacology at the Vanderbilt University (Nashville, TN, USA). From 1999 to 2002 he was group leader at the IKP. Between 2002 and 2004 he was acting Professor of Clinical Pharmacology and Clinical Toxicology at FAU, in 2004 he became Director of the Institute of Experimental and Clinical Pharmacology and Toxicology and Chair of Clinical Pharmacology and Clinical Toxicology at FAU. His major research interests are mechanisms underlying variable drug effects, in particular drug transporters as well as measures to improve medication safety. He published more than 170 original research articles and 49 reviews/commentries. He is among the Top 3% of highly cited researchers in the AD Scientific Index 2022, 2023 and 2024 and in the Top 2% in the Stanford Ranking of Highly Cited Researchers. His current h-index is 76 (more than 24.000 citations, Google Scholar). His work was/is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF), the German Ministry of Health (BMG), the German Cancer Association (Deutsche Krebshilfe) and several foundations. Moreover, among others, he has been vice chairmen of the Society of Clinical Pharmacology within the German Society of Pharmacology and Toxicology (DGPT) and member of the council of the European Association for Clinical Pharmacology and Therapeutics (EACPT); he has been or is active in ethics committees as member, vice chairman or chairman, is chair of the drug utilization committee of the University Hospital Erlangen and chairman of the steering board of the Center of Clinical Studies of the University Hospital Erlangen.